{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:34:18Z","timestamp":1760236458510,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer therapies targeting the vascular endothelial growth factor (VEGF) signaling pathway can lead to renal damage by disrupting the glomerular ultrafiltration apparatus. The objective of the current study was to identify sensitive biomarkers for VEGF inhibition-induced glomerular changes in rats. Male Sprague-Dawley rats were administered an experimental VEGF receptor (VEGFR) inhibitor, ABT-123, for seven days to investigate the correlation of several biomarkers with microscopic and ultrastructural changes. Glomeruli obtained by laser capture microdissection were also subjected to gene expression analysis to investigate the underlying molecular events of VEGFR inhibition in glomerulus. ABT-123 induced characteristic glomerular ultrastructural changes in rats, including fusion of podocyte foot processes, the presence of subendothelial electron-dense deposits, and swelling and loss of fenestrations in glomerular endothelium. The subtle morphological changes cannot be detected with light microscopy or by changes in standard clinical chemistry and urinalysis. However, urinary albumin increased 44-fold as early as Day three. Urinary \u03b22-microglobulin levels were also increased. Other urinary biomarkers that are typically associated with tubular injury were not significantly impacted. Such patterns in urinary biomarkers can provide valuable diagnostic insight to VEGF inhibition therapy-induced glomeruli injuries.<\/jats:p>","DOI":"10.3390\/ijms222312629","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T04:48:37Z","timestamp":1638247717000},"page":"12629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers"],"prefix":"10.3390","volume":"22","author":[{"given":"Yi","family":"Yang","sequence":"first","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Kowalkowski","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Ciurlionis","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne R.","family":"Buck","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith B.","family":"Glaser","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Albert","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A. G.","family":"Blomme","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40620-016-0311-8","article-title":"Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)","volume":"30","author":"Cosmai","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): An 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","article-title":"Renal adverse effects of sunitinib and its clinical significance: A single-center experience in Korea","volume":"29","author":"Baek","year":"2014","journal-title":"Korean J. Intern. Med."},{"key":"ref_10","unstructured":"(2009). Avastin (Bevacizumab) [Product Insert], Genentech."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1523-1755.2003.00840.x","article-title":"Pathophysiology of proteinuria","volume":"63","author":"Bazzi","year":"2003","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt.1625","article-title":"Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1289\/ehp.6683","article-title":"Identification of putative gene based markers of renal toxicity","volume":"112","author":"Amin","year":"2004","journal-title":"Environ. Health Perspect."},{"key":"ref_15","unstructured":"Food Drug Administration Center for Drugs Evaluation Research (2009). Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium, Food Drug Administration Center for Drugs Evaluation Research."},{"key":"ref_16","unstructured":"Food Drug Administration Center for Drugs Evaluation Research (2010). Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the ILSI-HESI Nephrotoxicity Working Group, Food Drug Administration Center for Drugs Evaluation Research."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nbt.1622","article-title":"Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nbt.1624","article-title":"Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury","volume":"28","author":"Yu","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/toxsci\/kfw038","article-title":"Rat Urinary Osteopontin and Neutrophil Gelatinase-Associated Lipocalin Improve Certainty of Detecting Drug-Induced Kidney Injury","volume":"151","author":"Phillips","year":"2016","journal-title":"Toxicol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1210\/mend.15.11.0734","article-title":"Adult Tissue Angiogenesis: Evidence for Negative Regulation by Estrogen in the Uterus","volume":"15","author":"Ma","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","first-page":"682","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Patey","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2020.12.031","article-title":"Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma","volume":"501","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"481520","DOI":"10.1155\/2012\/481520","article-title":"Mechanisms of glomerular albumin filtration and tubular reabsorption","volume":"2012","author":"Tojo","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ki.5002041","article-title":"The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states","volume":"71","author":"Russo","year":"2007","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1681\/ASN.2013090950","article-title":"The proximal tubule and albuminuria: Really!","volume":"25","author":"Dickson","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semnephrol.2007.01.002","article-title":"Albuminuria: A target for treatment of type 2 diabetic nephropathy","volume":"Volume 27","year":"2007","journal-title":"Seminars in Nephrology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00654.2010","article-title":"Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury","volume":"300","author":"Ware","year":"2011","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.V991723","article-title":"Beta-2 microglobulin in renal disease","volume":"9","author":"Miyata","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1681\/ASN.2004040287","article-title":"Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study","volume":"16","author":"Branten","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/QAD.0000000000001070","article-title":"Urinary \u03b22 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy","volume":"30","author":"Nishijima","year":"2016","journal-title":"AIDS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1021\/jm050458h","article-title":"Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors","volume":"48","author":"Dai","year":"2005","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:36Z","timestamp":1760168076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":35,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222312629"],"URL":"https:\/\/doi.org\/10.3390\/ijms222312629","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}